[ad_1]
Seoul, Korea, July 23, 2021 /PRNewswire-PRWeb/–Deep Bio, a leading digital pathology and cancer diagnostic company, today announced the renewal of a research collaboration agreement with the Dana-Farber Cancer Institute to evaluate prostate cancer tumors. This collaboration with Dana-Farber is part of the Men of African Descent and Prostate Cancer (MADCaP) Alliance, a global collaboration designed to assess the high burden of prostate cancer in the sub-Saharan African (SSA) population. Dana-Farber is the main teaching subsidiary Harvard Medical School And a founding member of the Dana-Farber/Harvard Cancer Center, which is the largest comprehensive cancer center designated by the National Cancer Institute (NCI) in the United States.
This research project will investigate whether Deep Bio’s deep learning algorithm DeepDx® Prostate can be used as an aid for pathologists to diagnose pathological specimens. Tumor tissue images collected from eight independent centers in sub-Saharan Africa will be processed and analyzed by DeepDx® Prostate. These AI-based pathology readings will…
The full story can be found on Benzinga.com
[ad_2]
Source link
